SG11201404451TA - Macrocyclic derivatives for the treatment of proliferative diseases - Google Patents

Macrocyclic derivatives for the treatment of proliferative diseases

Info

Publication number
SG11201404451TA
SG11201404451TA SG11201404451TA SG11201404451TA SG11201404451TA SG 11201404451T A SG11201404451T A SG 11201404451TA SG 11201404451T A SG11201404451T A SG 11201404451TA SG 11201404451T A SG11201404451T A SG 11201404451TA SG 11201404451T A SG11201404451T A SG 11201404451TA
Authority
SG
Singapore
Prior art keywords
treatment
proliferative diseases
macrocyclic derivatives
macrocyclic
derivatives
Prior art date
Application number
SG11201404451TA
Other languages
English (en)
Inventor
Simon Bailey
Benjamin Joseph Burke
Michael Raymond Collins
Jingrong Jean Cui
Judith Gail Deal
Robert Louis Hoffman
Qinhua Huang
Ted William Johnson
Robert Steven Kania
John Charles Kath
Phuong Thi Quy Le
Michele Ann Mctigue
Cynthia Louise Palmer
Paul Francis Richardson
Neal William Sach
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48142828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201404451T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of SG11201404451TA publication Critical patent/SG11201404451TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11201404451TA 2012-03-06 2013-02-20 Macrocyclic derivatives for the treatment of proliferative diseases SG11201404451TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261607485P 2012-03-06 2012-03-06
US201361759307P 2013-01-31 2013-01-31
PCT/IB2013/051391 WO2013132376A1 (en) 2012-03-06 2013-02-20 Macrocyclic derivatives for the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
SG11201404451TA true SG11201404451TA (en) 2014-09-26

Family

ID=48142828

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201404451TA SG11201404451TA (en) 2012-03-06 2013-02-20 Macrocyclic derivatives for the treatment of proliferative diseases

Country Status (46)

Country Link
US (2) US8680111B2 (ja)
EP (1) EP2822953B9 (ja)
JP (2) JP5823066B2 (ja)
KR (1) KR101692600B1 (ja)
CN (1) CN104169286B (ja)
AP (1) AP2014007881A0 (ja)
AR (1) AR090230A1 (ja)
AU (1) AU2013229173B2 (ja)
BR (1) BR112014022106B1 (ja)
CA (1) CA2863892C (ja)
CL (1) CL2014002084A1 (ja)
CO (1) CO7061081A2 (ja)
CR (1) CR20140370A (ja)
CY (2) CY1118771T1 (ja)
DK (1) DK2822953T5 (ja)
DO (1) DOP2014000188A (ja)
EA (1) EA026155B9 (ja)
ES (1) ES2621220T3 (ja)
FR (1) FR19C1062I2 (ja)
GE (1) GEP201606560B (ja)
GT (1) GT201400187A (ja)
HK (1) HK1199247A1 (ja)
HR (1) HRP20170287T2 (ja)
HU (2) HUE034118T2 (ja)
IL (1) IL234062A (ja)
LT (2) LT2822953T (ja)
LU (1) LUC00131I2 (ja)
MD (1) MD4590C1 (ja)
ME (1) ME02630B (ja)
MX (1) MX350844B (ja)
MY (1) MY169142A (ja)
NI (1) NI201400102A (ja)
NL (1) NL301006I2 (ja)
NO (1) NO2019034I1 (ja)
NZ (1) NZ627900A (ja)
PE (1) PE20142339A1 (ja)
PH (1) PH12014501992B1 (ja)
PL (1) PL2822953T3 (ja)
PT (1) PT2822953T (ja)
RS (1) RS55814B1 (ja)
SG (1) SG11201404451TA (ja)
SI (1) SI2822953T1 (ja)
TW (1) TWI476199B (ja)
UY (1) UY34657A (ja)
WO (1) WO2013132376A1 (ja)
ZA (1) ZA201406244B (ja)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2953931T3 (pl) 2013-01-31 2017-09-29 Vertex Pharmaceuticals Incorporated Pirydonoamidy jako modulatory kanałów sodowych
ES2656189T3 (es) 2013-06-28 2018-02-26 Pfizer Inc. Formas sólidas de un inhibidor macrocíclico de quinasa
CN104513253A (zh) * 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
NZ760006A (en) 2013-12-13 2022-07-29 Vertex Pharma Prodrugs of pyridone amides useful as modulators of sodium channels
ES2735729T3 (es) 2014-01-24 2019-12-20 Turning Point Therapeutics Inc Macrociclos de diarilo como moduladores de proteínas cinasas
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
CN103772272A (zh) * 2014-03-04 2014-05-07 定陶县友帮化工有限公司 2-boc-氨基-3-羟基-5-溴吡啶的合成方法
US10159663B2 (en) * 2014-08-20 2018-12-25 Teligene Ltd. Substituted macrocycles useful as kinases inhibitors and methods of use thereof
WO2016026423A1 (en) * 2014-08-20 2016-02-25 Teligene Ltd Substituted macrocycles useful as kinases inhibitors and methods of use thereof
WO2016061097A1 (en) * 2014-10-13 2016-04-21 Atrin Pharmaceuticals LLC Ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors
CN107207471B (zh) 2014-12-02 2020-06-26 伊尼塔公司 用于治疗神经母细胞瘤的组合
JP6741596B2 (ja) * 2015-01-16 2020-08-19 中外製薬株式会社 併用医薬
US10316044B2 (en) * 2015-07-02 2019-06-11 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
BR112018000297A2 (pt) 2015-07-06 2018-09-04 Tp Therapeutics Inc polimorfo de macrociclo de diarila
BR112018001065A2 (pt) 2015-07-21 2018-09-11 Tp Therapeutics, Inc. macrociclos diarila quirais e usos dos mesmos
FI3798222T3 (fi) 2015-07-31 2023-11-28 Pfizer Lorlatinibin vapaan emäksen kidemuoto
CA3000386A1 (en) 2015-09-30 2017-04-06 Merck Patent Gmbh Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
AU2016370846B2 (en) 2015-12-18 2022-08-25 Ignyta, Inc. Combinations for the treatment of cancer
ES2812336T3 (es) * 2016-03-03 2021-03-16 Shenzhen Targetrx Inc Macrocíclico y composición que comprende el mismo
CN105732355A (zh) * 2016-04-07 2016-07-06 戊言医药科技（上海）有限公司 1-(5-氟-2-碘苯基)乙酮的制备方法
CN105646355A (zh) * 2016-04-07 2016-06-08 戊言医药科技（上海）有限公司 3-(羟甲基)-1-甲基-吡唑-5-甲腈的制备方法
JP2019510774A (ja) * 2016-04-08 2019-04-18 ファイザー・インク ロルラチニブマレイン酸塩の結晶質形態
WO2017180723A1 (en) * 2016-04-12 2017-10-19 Atrin Pharmaceuticals LLC Ataxia telengiectasia and rad3-related (atr) inhibitors and methods of their use
CN105801603B (zh) * 2016-04-13 2018-10-02 成都倍特药业有限公司 一种具有大环结构的alk抑制剂及其制备方法
MX2019001125A (es) 2016-07-28 2019-06-12 Tp Therapeutics Inc Inhibidores de cinasa macrociclica.
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
WO2018137679A1 (en) * 2017-01-25 2018-08-02 Teligene Ltd Process for the Preparation of (10R) -7- (2-aminoacetyl) amino-12-fluoro-2, 10, 16-trimethyl-15-oxo-10, 15, 16, 17-tetrahydro-2H-8, 4- (metheno) pyrazolo [4, 3-h] [2, 5, 11] -benzoxadiazacyclotetradecine-3-carbonitrile
UA124857C2 (uk) 2017-05-16 2021-12-01 Вертекс Фармасьютикалз Інкорпорейтед Дейтеровані піридонаміди і їх проліки як модулятори натрієвих каналів
KR20200020911A (ko) 2017-06-30 2020-02-26 바이엘 애니멀 헬스 게엠베하 새로운 아자퀴놀린 유도체
JP7203083B2 (ja) 2017-07-19 2023-01-12 イグナイタ インコーポレイテッド エントレクチニブを含む薬学的組成物
BR112020001695A2 (pt) 2017-07-28 2020-07-21 Turning Point Therapeutics, Inc. compostos macrocíclicos e usos dos mesmos
JP7153069B2 (ja) * 2017-10-10 2022-10-13 ファイザー・インク ロルラチニブ遊離塩基水和物の結晶形態
EP3697390A1 (en) 2017-10-17 2020-08-26 Ignyta, Inc. Pharmaceutical compositions and dosage forms
US11179412B2 (en) 2017-12-04 2021-11-23 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating conditions involving elevated inflammatory response
ES2929467T3 (es) 2017-12-19 2022-11-29 Turning Point Therapeutics Inc Compuestos macrocíclicos para tratar enfermedades
CN111918650A (zh) 2018-02-12 2020-11-10 沃泰克斯药物股份有限公司 治疗疼痛的方法
WO2019168874A1 (en) 2018-02-27 2019-09-06 The Research Foundation For The State University Of New York Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
EP3784675A1 (en) 2018-04-23 2021-03-03 Pliva Hrvatska D.O.O. Solid state forms of lorlatinib and their preparation
WO2019210835A1 (zh) * 2018-05-04 2019-11-07 正大天晴药业集团股份有限公司 作为蛋白激酶调节剂的二芳基大环化合物
CN108621206B (zh) * 2018-05-07 2020-08-14 昆山国显光电有限公司 手套箱系统以及手套箱系统的保养方法
CA3113408A1 (en) * 2018-09-18 2020-03-26 Kabushiki Kaisha Yakult Honsha Cancer combination therapy using quinoline carboxamide derivative
CN109232607A (zh) * 2018-09-20 2019-01-18 沈阳药科大学 劳拉替尼的合成方法
CN109081810A (zh) * 2018-09-20 2018-12-25 沈阳药科大学 1-甲基-3–((甲氨基)甲基)-1h-吡唑-5-腈的合成方法
EP3872081A4 (en) * 2018-11-28 2022-04-27 Shenzhen TargetRx, Inc. PROCESS FOR PRODUCING A DEUTERED MACROCYCLIC COMPOUND
EP3903828A4 (en) 2018-12-21 2022-10-05 Daiichi Sankyo Company, Limited COMBINATION OF AN ANTIBODY-DRUG CONJUGATE AND A KINASE INHIBITOR
CN109651398B (zh) * 2019-01-25 2021-07-30 安庆多辉生物科技有限公司 一种合成劳拉替尼的溴代物中间体及催化合成劳拉替尼的方法
CN109651397A (zh) * 2019-01-25 2019-04-19 安庆多辉生物科技有限公司 一种劳拉替尼中间体及制备劳拉替尼的方法
CN109651418A (zh) * 2019-01-25 2019-04-19 安庆多辉生物科技有限公司 一种劳拉替尼原料药合成中间体及有机金属钯催化偶联制备劳拉替尼的方法
CN111499514A (zh) * 2019-01-31 2020-08-07 连云港润众制药有限公司 一种罗沙司他中间体的制备方法
US11976069B2 (en) 2019-03-21 2024-05-07 Merck Sharp & Dohme Llc Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection
JP7345901B2 (ja) * 2019-05-14 2023-09-19 テリジーン リミテッド キナーゼ阻害剤として有用な置換大員環類
WO2021011345A1 (en) * 2019-07-18 2021-01-21 Pliva Hrvatska D.O.O Crystalline lorlatinib : fumaric acid and solid state form thereof
CN112321604A (zh) * 2019-08-05 2021-02-05 华东理工大学 大环类jak2抑制剂及其应用
CN110483551B (zh) * 2019-08-30 2021-10-22 北京赛思源生物医药技术有限公司 一种劳拉替尼游离碱的晶体
WO2021069571A1 (en) 2019-10-10 2021-04-15 Sandoz Ag Polymorph of lorlatinib
CN112812128B (zh) * 2019-11-18 2024-04-02 正大天晴药业集团股份有限公司 作为alk和ros调节剂的大环化合物
CN112824417A (zh) * 2019-11-21 2021-05-21 上海天慈国际药业有限公司 一种劳拉替尼的制备方法
US11834441B2 (en) 2019-12-06 2023-12-05 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
CN111170908B (zh) * 2020-01-09 2021-08-17 北京印刷学院 一种2，4-二甲基-3-甲磺酰基卤苯的合成方法
US20230117684A1 (en) 2020-03-05 2023-04-20 Pfizer Inc. Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor
EP4146205A4 (en) 2020-05-05 2024-05-29 Nuvalent Inc HETEROAROMATIC MACROCYCLIC ETHER-BASED CHEMOTHERAPY AGENTS
CN115916754A (zh) * 2020-05-05 2023-04-04 纽威伦特公司 杂芳族大环醚化学治疗剂
US20230174554A1 (en) * 2020-05-18 2023-06-08 Shenzhen TargetRx. Inc. Solid form of macrocyclic compound, preparation therefor and use thereof
MX2023000503A (es) * 2020-07-10 2023-02-09 Blossomhill Therapeutics Inc Macrociclos y su uso.
JP2023553835A (ja) * 2020-12-17 2023-12-26 ブロッサムヒル・セラピューティクス・インコーポレイテッド 大環状化合物およびそれらの使用
CN114805371B (zh) * 2021-01-19 2024-05-24 江苏开元药业有限公司 含2-氨基嘧啶大环类化合物及其制备方法和用途
WO2022182845A1 (en) * 2021-02-25 2022-09-01 Blossomhill Therapeutics, Inc. Macrocycles and their use
EP4320153A1 (en) 2021-04-09 2024-02-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of anaplastic large cell lymphoma
CN115246843A (zh) * 2021-04-26 2022-10-28 苏州东南药业股份有限公司 一类十四元稠环衍生物及其应用
EP4347031A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
CA3231813A1 (en) * 2021-10-01 2023-04-06 Sibao CHEN Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
WO2023156983A1 (en) 2022-02-21 2023-08-24 Universidade Nova De Lisboa Compounds and compositions for neurodegenerative diseases
EP4230201A1 (en) 2022-02-21 2023-08-23 Universidade Nova De Lisboa Composition for treating neurodegenerative diseases
WO2024086634A1 (en) * 2022-10-19 2024-04-25 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
CN115746023A (zh) * 2022-10-27 2023-03-07 复旦大学 一种作为蛋白激酶抑制剂的含吲唑结构的杂环大环化合物及其制备方法
WO2024046512A2 (zh) * 2022-12-01 2024-03-07 中国医药研究开发中心有限公司 含氮大环类化合物及其制备方法和医药用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
PT2476667E (pt) 2003-02-26 2014-09-18 Sugen Inc Compostos de aminoheteroarilo como inibidores da proteína quinase
US7151096B2 (en) 2003-03-05 2006-12-19 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
JO2785B1 (en) * 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives
RU2346996C2 (ru) 2004-06-29 2009-02-20 ЮРОПИЭН НИКЕЛЬ ПиЭлСи Усовершенствованное выщелачивание основных металлов
BRPI0514458A (pt) 2004-08-25 2008-06-10 Pfizer triazolbenzodiazepinas e seu uso como antagonistas de vasopressina
CA2578066C (en) * 2004-08-26 2011-10-11 Pfizer Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
WO2006021881A2 (en) 2004-08-26 2006-03-02 Pfizer Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
EP1710246A1 (en) 2005-04-08 2006-10-11 Schering Aktiengesellschaft Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer
DK1959955T3 (da) 2005-12-05 2011-02-07 Pfizer Prod Inc Fremgangsmåde til behandling af abnorm cellevækst
KR101146852B1 (ko) 2005-12-05 2012-05-16 화이자 프로덕츠 인크. Ｃ?ｍｅｔ／ｈｇｆｒ 억제제의 다형체
WO2008088881A1 (en) 2007-01-19 2008-07-24 Xcovery, Inc. Kinase inhibitor compounds
CL2008000629A1 (es) 2007-03-01 2008-08-29 Chugai Pharmaceutical Co Ltd Compuestos macrociclicos derivados de 6-aril-4-mercapto-[1.3.5]triazina/[1.3]pirimidin-2-amina; composicion farmaceutica, utiles en el tratamiento del cancer.
AP2009004985A0 (en) * 2007-03-13 2009-10-31 Pfizer Prod Inc Erythromycin-based macrolides
EP2265270A1 (en) * 2008-02-04 2010-12-29 OSI Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
EP2274288A2 (en) * 2008-04-24 2011-01-19 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
CA2726554C (en) * 2008-06-06 2015-02-24 Sanofi-Aventis Macrocyclic urea and sulfamide derivatives as inhibitors of tafia
MX2011002470A (es) * 2008-09-08 2011-04-05 Merck Patent Gmbh Pirimidinas macrociclicas como inhibidores de aurora cinasa.
WO2010085597A1 (en) 2009-01-23 2010-07-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
WO2011047926A1 (en) 2009-10-21 2011-04-28 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Non-natural macrocyclic amide hdac6 inhibitor compounds and their uses as therapeutic agents
US8383793B2 (en) * 2010-04-15 2013-02-26 St. Jude Children's Research Hospital Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
EP2566858A2 (en) * 2010-05-04 2013-03-13 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
EP2918588B1 (en) * 2010-05-20 2017-05-03 Array Biopharma, Inc. Macrocyclic compounds as TRK kinase inhibitors
US8975232B2 (en) 2010-07-29 2015-03-10 President And Fellows Of Harvard College Macrocyclic kinase inhibitors and uses thereof
WO2012125603A1 (en) 2011-03-16 2012-09-20 Cephalon, Inc. Macrocyclic compounds as alk, fak and jak2 inhibitors

Also Published As

Publication number Publication date
HRP20170287T1 (hr) 2017-04-21
EA026155B1 (ru) 2017-03-31
PE20142339A1 (es) 2015-01-15
CR20140370A (es) 2014-08-21
NL301006I2 (nl) 2020-04-14
TWI476199B (zh) 2015-03-11
AU2013229173A1 (en) 2014-08-21
EA201491394A1 (ru) 2015-05-29
AR090230A1 (es) 2014-10-29
LTC2822953I2 (lt) 2020-12-28
JP5823066B2 (ja) 2015-11-25
LUC00131I2 (ja) 2020-07-16
HUS1900040I1 (hu) 2019-09-30
EA026155B9 (ru) 2017-06-30
US20140135339A1 (en) 2014-05-15
CL2014002084A1 (es) 2014-11-03
HRP20170287T2 (hr) 2017-11-03
CY1118771T1 (el) 2017-07-12
UY34657A (es) 2013-10-31
FR19C1062I2 (fr) 2020-09-04
MD4590C1 (ro) 2019-03-31
BR112014022106A2 (pt) 2017-07-11
CA2863892C (en) 2016-08-30
MX350844B (es) 2017-09-22
WO2013132376A1 (en) 2013-09-12
EP2822953B9 (en) 2017-06-21
KR20140137414A (ko) 2014-12-02
ME02630B (me) 2017-06-20
CA2863892A1 (en) 2013-09-12
ES2621220T9 (es) 2017-11-23
CY2019033I2 (el) 2019-11-27
HK1199247A1 (zh) 2015-06-26
KR101692600B1 (ko) 2017-01-03
MD20140086A2 (ro) 2015-01-31
DK2822953T5 (en) 2017-09-11
HUE034118T2 (en) 2018-01-29
US9133215B2 (en) 2015-09-15
LT2822953T (lt) 2017-04-10
BR112014022106B1 (pt) 2022-08-02
ZA201406244B (en) 2015-05-27
GEP201606560B (en) 2016-10-25
LUC00131I1 (ja) 2019-10-11
MY169142A (en) 2019-02-18
MX2014010716A (es) 2014-09-22
FR19C1062I1 (ja) 2019-11-22
NI201400102A (es) 2015-03-05
CN104169286A (zh) 2014-11-26
GT201400187A (es) 2015-10-15
RS55814B1 (sr) 2017-08-31
EP2822953B1 (en) 2017-02-01
PT2822953T (pt) 2017-04-06
IL234062A (en) 2017-08-31
US20130252961A1 (en) 2013-09-26
EP2822953A1 (en) 2015-01-14
TW201350484A (zh) 2013-12-16
PH12014501992A1 (en) 2014-11-24
AP2014007881A0 (en) 2014-08-31
CO7061081A2 (es) 2014-09-19
JP6002825B2 (ja) 2016-10-05
US8680111B2 (en) 2014-03-25
DK2822953T3 (en) 2017-04-03
PL2822953T3 (pl) 2017-07-31
CN104169286B (zh) 2016-06-08
SI2822953T1 (sl) 2017-04-26
NO2019034I1 (no) 2019-08-19
JP2015510879A (ja) 2015-04-13
ES2621220T3 (es) 2017-07-03
MD4590B1 (ro) 2018-08-31
DOP2014000188A (es) 2014-11-16
CY2019033I1 (el) 2019-11-27
NZ627900A (en) 2016-08-26
LTPA2019519I1 (lt) 2019-11-11
PH12014501992B1 (en) 2014-11-24
AU2013229173B2 (en) 2017-06-01
JP2016041709A (ja) 2016-03-31

Similar Documents

Publication Publication Date Title
HUS1900040I1 (hu) Makrociklusos származékok proliferatív betegségek kezelésére
HK1207302A1 (en) Derivatives of azaindazole or diazaindazole type for treating pain
IL263661A (en) Combination therapy for the treatment of glioblastoma
HK1204605A1 (en) Functionalized thieno-indole derivatives for the treatment of cancer
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
HUP1100290A2 (en) Combination compositions for the treatment of proliferative diseases
HK1208454A1 (zh) 治療細菌性疾病的嘧啶衍生物
IL233493A (en) Imidazopyridine derivatives for cancer treatment
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
IL236870B (en) History of hydroxystatin for the treatment of osteoarthritis
HK1202118A1 (en) Piperazinyl derivatives for the treatment of cancer
HUE048942T2 (hu) Antraciklin-származékok tumorbetegségek kezeléséhez